Future prospectives for the management of chronic hepatitis B

Table 4 Treatment outcomes after 1 year of treatment for different antiviral drugs for the management of lamivudine resistant chronic hepatitis B for both HBeAg positive and HBeAg negative patients

	n	Author; Journal; Yr	HbeAg loss (%)	HBeAg serocon-version(%)	HbsAg loss (%)	Decline viralload (log10 copies/mL)	HBV DNA negativity (%)	ALT normalisation (%)	Histological improvement(%)	Resistance (%)
HBeAg pos
PEG-IFN-α 2b	16	Leemans; J Hepatology; 2006[38]	13	13	6	0.6	64	19
Adefovir	45	Buti; Hepatology; 2004[165]		13	0		337	51
Adefovir	19	Peters; Gastroenterology; 2004[118]	16	11		4.0	265	47		0
HBeAg neg
PEG-IFN-α 2b	20	Vassiliadis; WJG; 2006[39]					54	10
Adefovir	75	Buti; Hepatology; 2004[165]			0		517	63
Adefovir	20	Manilakopoulos; Hepatology; 2005[119]				3.3		72		5
Adefovir + lamivudine	44	Manilakopoulos; Hepatol; 2005[119]				3.3		87		0
Adefovir	26	Koskinas; J Hepatology; 2005[166]				2.5		92		4
Adefovir + lamivudine	74	Lampertico; Hepatology; 2005[167]					786	82		0
Adefovir + lamivudine	23	Koskinas; J Hepatology; 2006[166]				2.8		87		0
Adefovir + lamivudine	49	Vassiliadis; AP&T; 2005[168]			0	6.5	574	75
Mixed
Adefovir	18	van Bömmel; Hepatology; 2004[17]	19		0	2.8	444
Adefovir + lamivudine	20	Peters; Gastroenterology; 2004[118]	17	6		3.6	355	53		0
Adefovir	57	Lee; Hepatology; 2006[102]	20			2.4	193	60		18
Adefovir + lamivudine	46	Perrillo; Gastroenterology; 2004[61]	15	8	0	4.6	201	30
Adefovir ± lamivudine11	126	Schiff; Hepatology; 2003[59]				4.1	814	76		0
Adefovir + lamivudine	34	Moriconi; J Hepatology; 2006[169]					681
Adefovir ± lamivudine	65	Hann; J Hepatology; 2006[132]	710			2.4	215
Entecavir	42	Chang; Gastroenterology; 2005[170]	11	4		5.6	264	68		0
Entecavir	141	Sherman; Gastroenterology; 2006[129]	10	11		5.1	272	61	55	7
Entecavir	42	Karino; J Hepatology; 2006[171]		15		3.8	604	78	60	0
Entecavir	116	Yao; J Hepatology; 2006[172]	8	6		5.8	272	85
Tenofovir ± lamivudine9	35	van Bömmel; Hepatology; 2004[17]				5.5	1004			0
Tenofovir ± lamivudine	44	Hann; J Hepatology; 2006[132]	410			5.0	865
Tenofovir + lamivudine9	11	Van der Eijk; J Viral Hepatitis; 2005[173]	10	0	0	5.0		91
Tenofovir9	10	Dore; J Infect Dis; 2004[174]	20	10		4.9		25
Tenofovir9	12	Núñez; Aids; 2002[175]		11	8	3.8	581
Tenofovir9	20	Nelson; Aids; 2003[176]		25		4.0
Tenofovir9	12	Benhamou; NEJM; 2003[177]	0	0	0	3.8

Efficacy measures presented are off-treatment responses for PEG-interferon and on-treatment responses for nucleos(t)ide analogues.

¹LLD 200 copies/mL;

²LLD 300 copies/mL;

³LLD 366 copies/mL;

⁴LLD 400 copies/mL;

⁵LLD 1.0 × 10³ copies/mL;

⁶LLD 2.0 × 10³ copies/mL ;

⁷LLD 1.0 × 10⁵ copies/mL; ⁸results after 24 wk of treatment;

⁹including HIV/HBV co-infected patients ± some patients with, some patients without combination therapy;

¹⁰after 24 mo of treatment;

¹¹patients with decompensated cirrhosis.